DISCUSSION
HBV infections
This analysis characterized the plasma PK of single and multiple doses of GSK3389404 in participants with chronic HBV infections and compared the GSK3389404 plasma PK across Asian-Pacific populations from mainland China, Hong Kong, Japan, South Korea, the Philippines, and Singapore. The data showed that the GSK3389404 plasma concentration versus time profiles, PK parameters, and exposure were similar across the Asian-Pacific populations assessed.In studies enrolling patients with the same ethnic background, PK, efficacy, and safety profiles are expected to be similar, although this has not yet been established (There is a paucity of published data assessing the PK of ASOs across different countries within Asia or between Asians and non-Asians, which may promulgate the continued requirement of ESS. Differences in PK across the Asian-Pacific populations were not expected, and this is confirmed by the results of this analysis. GSK3389404 metabolism and elimination do not involve hepatic enzymes and transporters. The elimination of GSK3389404 is expected to be via metabolism in the tissue and renal elimination of shortened chain fragments, based on studies with other ASOs (The GSK3389404 plasma PK in participants with chronic HBV infections in this study (GSK study 205670) are consistent with those reported in a previous study in non-Asian healthy participants (GSK study 202007) (The increase in the GSK3389404 plasma CThe observed GSK3389404 plasma PK profiles were similar to those of bepirovirsen (This analysis has several limitations. The PK sampling schedules of the full PK profiles in Part 1 and Part 2 of the Japanese substudy were different. In Part 1, the 12 h and 24 h PK samples were not collected due to operational constraints. As a result, the 0 to 24 h PK profiles, AUC from time zero (predose) to 24 h postdose (AUCIn conclusion, the GSK3389404 plasma PK were similar to those observed in the previous study in non-Asian healthy participants and with other ASOs (